Skip to content

Norepinephrine Versus Ephedrin for Prevention of Post Spinal Anesthesia in Cesarean Section

Norepinephrine Versus Ephedrin for Prevention of Post Spinal Anesthesia in Cesarean Section

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03719625
Enrollment
200
Registered
2018-10-25
Start date
2019-01-02
Completion date
2019-05-30
Last updated
2018-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean, Maternal Hypotension Syndrome

Brief summary

Spinal anesthesia is still the gold standard anesthetic method for elective and urgent cesarean section, the post spinal hypotension remains the most frequent complication of this procedure and is still responsible of considerable maternel and fetal morbidity. It is recommanded to prevent this post spinal hypotension with fluid coloading and prophylactic vasopressors administration. The aim of this study is to compare the efficency and the safety of norepinephrin and ephedrin prophylactic administration to reduce the incidence of post spinal hypotension in cesarean section.

Detailed description

Spinal anesthesia is still the gold standard anesthetic method for elective and urgent cesarean section, the post spinal hypotension remains the most frequent complication of this procedure and is still responsible of considerable maternel and fetal morbidity. It is recommanded to prevent this post spinal hypotension with fluid coloading and prophylactic vasopressors administration. The prophylactic use of norepinephrin and phenylephrin has been validated by several studies, but few data are published concerning the comparaison between norepinephrin and ephedrine as preventive vasopressors in cesarean section; these molecules act on alpha and beta adrenergic receptors and could provide better maternal hemodynamics in parturients undergoing cesarean section under spinal anesthesia. The aim of this study is to compare the efficency and the safety of norepinephrin and ephedrin prophylactic administration to reduce the incidence of post spinal hypotension in cesarean section.

Interventions

DRUGEphedrine

Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section

DRUGNorepinephrine

Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section

Sponsors

Mongi Slim Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Intervention model description

controlled, prospective, randomised trial comparing 2 interventions

Eligibility

Sex/Gender
FEMALE
Age
15 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* full termed parturients scheduled for elective or semi urgent cesarean section under spinal anesthesia * AGE\>15 years * ASA II status * No history of hypertension, preeclampsia or cardiopathy * BMI\<40

Exclusion criteria

* cesarean section under genearl anesthesia or epidural analgesia during labor

Design outcomes

Primary

MeasureTime frameDescription
Incidence of post spinal hypotensionduring the first 20 minutes after spinal anesthesiadecrease of systolic arterial blood pressure \> 20% baseline

Secondary

MeasureTime frameDescription
Incidence of bradycardiaduring the first 20 minutes after spinal anesthesiaheart rate\<50 beats/min
incidence of nausea and/or vomitingduring the first 20 minutes after spinal anesthesiaincidence of nausea and/or vomiting
Lowest systolic blood pressureuring the first 20 minutes after spinal anesthesiaLowest systolic blood pressure recorded after spinal anesthesia
fetal ph20min after spinal anesthesiafetal ph
fetal blood lactates20min after spinal anesthesiafetal blood lactates
Apgar score20min after spinal anesthesiaApgar score at 1 min, 5 min, 10 min

Contacts

Primary ContactAsma Ben Souissi, assistant professor
bsouissiasma@gmail.com0021698336883
Backup ContactMhamed Sami Mebazaa, Professor
msmebazaa@gmail.com0021622252589

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026